Tissue Regenix: Faster-than-anticipated recovery

Hardman & Co
[shareaholic app="share_buttons" id_name="post_below_content"]

Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. Interim results showed early signs of the benefits of its strategic activities over the past two years – the focus on commercial relationships, capacity expansion, restructuring to service demand, and recovery in elective surgeries after the pandemic. If the demand and sales progress continues, TRX will become EBITDA- and EBIT-positive in fiscal 2022.

  • Strategy: Tissue Regenix Group is building an international regenerative medicine business around its proprietary technology platforms, underpinned by compelling clinical outcomes. Expansion of manufacturing capabilities and some recovery in elective surgeries are driving sales momentum through distribution networks and strategic partners.
  • Interims: Underlying sales in 1H’21 were ahead of expectations, rising 21%, to £6.80m (£6.09m). Currency headwinds dented the reported numbers. Increased sales, coupled with restructuring benefits, resulted in a 45% improvement in underlying EBIT, to -£1.34m (-£2.42m). Gross cash at the period-end was £6.6m.
  • Outlook: Given the strong performance in 1H’21, coupled with increased manufacturing capacity and launch of new products, there is an understandable temptation to significantly upgrade forecasts. However, while underlying prospects are positive, our numbers reflect US COVID-19-related hospitalisations.
  • Risks: There has been some recovery in the number of elective surgeries in the US, but whether the pace of recovery can continue for the remainder of 2021 remains uncertain, especially given recent US data regarding COVID-19 infections and hospitalisations. Also, reported numbers will be impacted by forex headwinds.
  • Investment summary: Tissue Regenix Group has a portfolio of innovative regenerative products that are in demand from surgeons. Recent product launches and completion of Phase 1 of its capacity expansion programme will add to the positive momentum seen in 1H’21. TRX is extremely well-positioned to deliver sales growth, which is expected to result in further forecast uplifts and a re-rating of the shares when there is more certainty about the recovery in elective surgeries.

DOWNLOAD THE FULL REPORT

Share on:
Find more news, interviews, share price & company profile here for:

    NB Private Equity 2024 Results: Confirming the Model’s Long-term Growth Prospects (Video)

    Hardman & Co’s Mark Thomas explains why NB Private Equity Partners’ 2024 dip is masking a much stronger long-term growth story—one backed by impressive realisation multiples, stable EBITDA growth, and expanding investment opportunities.

    Chesnara plc 20 Years of Dividend Growth Backed by £1.5 Billion Acquisition Surge (Video)

    Dr Brian Moretta explains how disciplined deal-making, strong cash generation, and operational progress across the UK and Europe are reinforcing Chesnara’s position

    Arbuthnot Banking Group: Franchise Growth and 2025 Outlook (LON:ARBB)

    Discover how Arbuthnot Banking Group is thriving despite market challenges, with significant growth in specialist lending and wealth management in 2024.

    Apax Global Alpha: Stronger prospects for 2025 and beyond (LON:APAX)

    In a recent interview, Mark Thomas from Hardman & Co discusses Apax Global Alpha's (LON:APAX) recent performance, future growth, and investment strategies.

    Arbuthnot Banking Group Profits Dip but Franchise Growth Signals a Strategic Masterstroke (Video)

    Analyst Mark Thomas of Hardman & Co breaks down how the Group is building long-term shareholder value by expanding specialist lending, attracting new banking clients, and scaling its wealth management business.

      Search

      Search